Llama-derived phage display antibody arrays for FSHD

用于 FSHD 的源自美洲驼的噬菌体展示抗体阵列

基本信息

项目摘要

DESCRIPTION (provided by applicant): The aim of this project is to gain insight in the cellular and molecular processes leading to dysfunction of the neuromuscular system in FSHD patients by large scale analysis of protein homeostasis in tissues and cell lines of patients and controls. In the past few years, projects have been launched to study deregulation of biological pathways in FSHD on RNA level. These strategies include differential display and RNA profiling experiments on commercial and custom made DNA chips and arrays. Despite their limitations, DNA arrays are now one of the most commonly used and successful methods to determine the molecular and cellular aspects of many acquired and genetic diseases. It is anticipated that also for FSHD, this approach will provide a valuable contribution in understanding its pathology. Nevertheless, protein levels, including the level of modified proteins and the composition of protein complexes are of an order of importance larger to understand FSHD pathophysiology. Consequently there is a need for protein arrays. The llama antibody technology provides a unique opportunity to develop protein arrays. The power of the llama system for this purpose is that this animal makes single (heavy) chain antibodies. Using the genetic information for this single-chain repertoire for the construction of phage-display antibody libraries abolishes the need to combine heavy- and light-chains, one of the major drawbacks of conventional phage-display libraries. Moreover, these single-chain antibodies tend to have a very high affinity and stability. It has already been demonstrated that large naive and directed libraries of antibodies can be generated. Experience in cloning, production and isolation of these llama antibodies is available. We propose to generate muscle-specific antibody arrays derived from Llama single-chain phage-display clones. To this end, a Llama will be immunized with human muscle protein homogenates, and after peak response, a phage display library will be constructed. Antibody clones will be selected with a variety of selection procedures (e.g. with recombinant proteins or with muscle homogenates from different species) and arrayed on glass slides. Well characterized single chain antibody arrays will be used to study FSHD pathophysiology on fluorescently labeled protein homogenates of tissues and cell cultures of patients and controls. Evidently, these antibodies can also be used individually for specific immunohistochemical and immunocytochemical studies.
描述(由申请人提供):这个项目的目的是获得洞察力

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation.
从 Camelid 非免疫文库中选择可靠且可控的抗体片段,用于靶标验证。
  • DOI:
    10.1016/j.bbapap.2006.05.011
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Verheesen,Peter;Roussis,Andreas;deHaard,HansJ;Groot,ArjanJ;Stam,JordC;denDunnen,JohanT;Frants,RuneR;Verkleij,ArieJ;TheoVerrips,C;vanderMaarel,SilvèreM
  • 通讯作者:
    vanderMaarel,SilvèreM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SILVERE M VAN DER MAAREL其他文献

SILVERE M VAN DER MAAREL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SILVERE M VAN DER MAAREL', 18)}}的其他基金

The Genetic and Epigenetic Basis for FSHD
FSHD 的遗传和表观遗传基础
  • 批准号:
    8232180
  • 财政年份:
    2011
  • 资助金额:
    $ 12.5万
  • 项目类别:
Clonal isogenic and immortalized FSHD myoblasts with or without D4Z4 contraction
有或没有 D4Z4 收缩的克隆同基因永生化 FSHD 成肌细胞
  • 批准号:
    7978984
  • 财政年份:
    2010
  • 资助金额:
    $ 12.5万
  • 项目类别:
Identification of the gene defect underlying ICF2 syndrome
鉴定 ICF2 综合征背后的基因缺陷
  • 批准号:
    8080912
  • 财政年份:
    2010
  • 资助金额:
    $ 12.5万
  • 项目类别:
Clonal Isogenic and Immortalized FSHD Myoblasts with or without D4Z4 Contraction
有或没有 D4Z4 收缩的克隆同基因和永生化 FSHD 成肌细胞
  • 批准号:
    8138560
  • 财政年份:
    2010
  • 资助金额:
    $ 12.5万
  • 项目类别:
Identification of the gene defect underlying ICF2 syndrome
鉴定 ICF2 综合征背后的基因缺陷
  • 批准号:
    7953512
  • 财政年份:
    2010
  • 资助金额:
    $ 12.5万
  • 项目类别:
FSHD as a Disorder of Impaired RNA Biogenesis
FSHD 是一种 RNA 生物发生受损的疾病
  • 批准号:
    7493530
  • 财政年份:
    2007
  • 资助金额:
    $ 12.5万
  • 项目类别:
FSHD as a Disorder of Impaired RNA Biogenesis
FSHD 是一种 RNA 生物发生受损的疾病
  • 批准号:
    7290235
  • 财政年份:
    2007
  • 资助金额:
    $ 12.5万
  • 项目类别:
Llama-derived phage display antibody arrays for FSHD
用于 FSHD 的源自美洲驼的噬菌体展示抗体阵列
  • 批准号:
    6438421
  • 财政年份:
    2001
  • 资助金额:
    $ 12.5万
  • 项目类别:
Llama-derived phage display antibody arrays for FSHD
用于 FSHD 的源自美洲驼的噬菌体展示抗体阵列
  • 批准号:
    6534543
  • 财政年份:
    2001
  • 资助金额:
    $ 12.5万
  • 项目类别:
Project 1: Pathways and mechanisms repressing D4Z4 repeats
项目 1:抑制 D4Z4 重复序列的途径和机制
  • 批准号:
    9767871
  • 财政年份:
  • 资助金额:
    $ 12.5万
  • 项目类别:

相似海外基金

Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
  • 批准号:
    502607
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
  • 批准号:
    BB/Y002180/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Research Grant
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
  • 批准号:
    EP/Y024540/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Fellowship
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
  • 批准号:
    MR/Y003616/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
  • 批准号:
    MR/Y033698/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Operating Grants
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
  • 批准号:
    23H03716
  • 财政年份:
    2023
  • 资助金额:
    $ 12.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了